JP2003088334A - Composition for reducing cholesterol in blood - Google Patents

Composition for reducing cholesterol in blood

Info

Publication number
JP2003088334A
JP2003088334A JP09331299A JP9331299A JP2003088334A JP 2003088334 A JP2003088334 A JP 2003088334A JP 09331299 A JP09331299 A JP 09331299A JP 9331299 A JP9331299 A JP 9331299A JP 2003088334 A JP2003088334 A JP 2003088334A
Authority
JP
Japan
Prior art keywords
globulin
cholesterol
protein
reducing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP09331299A
Other languages
Japanese (ja)
Inventor
Mitsutaka Kono
光登 河野
Motohiko Hirotsuka
元彦 廣塚
Toshiaki Aoyama
敏明 青山
Yukio Hashimoto
征雄 橋本
Makoto Kito
誠 鬼頭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Oil Co Ltd
Original Assignee
Fuji Oil Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Oil Co Ltd filed Critical Fuji Oil Co Ltd
Priority to JP09331299A priority Critical patent/JP2003088334A/en
Priority to AU34549/00A priority patent/AU3454900A/en
Priority to PCT/JP2000/001994 priority patent/WO2000057898A1/en
Publication of JP2003088334A publication Critical patent/JP2003088334A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a composition for safely and efficiently reducing the concentration of cholesterol in the blood. SOLUTION: This composition for reducing the cholesterol in the blood contains 11S globulin fractionated from a soybean protein.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は大豆蛋白質から分画
された生理活性のひとつである血中コレステロール低減
能画分に関する。
TECHNICAL FIELD The present invention relates to a fraction capable of reducing blood cholesterol, which is one of physiological activities fractionated from soybean protein.

【0002】[0002]

【従来の技術】大豆蛋白質は植物性蛋白質の中で栄養性
が優れているだけでなく、近年では様々な生理活性効果
が見い出され、生理機能剤としても注目される食品素材
である。
2. Description of the Related Art Soybean protein is a food material which not only has excellent nutritional properties among vegetable proteins but also has various physiologically active effects in recent years, and is attracting attention as a physiological function agent.

【0003】大豆蛋白質の持つ血中コレステロール低減
能についてはよく知られており、それは大豆蛋白質のあ
る成分が、コレステロールの原因となる胆汁酸等と特異
的に結合し、そのまま糞便として排泄されると言われて
いる。さらに、このコレステロール低減の効果を謳った
食品(大豆プロテイン食品;「大豆からあげ」不二製油
株式会社製)が厚生省許可特定保健用食品にもなってい
る。
It is well known that blood soybean protein has the ability to reduce blood cholesterol. When a certain component of soybean protein specifically binds to bile acids and the like which cause cholesterol, it is excreted as it is as feces. It is said. Furthermore, foods that claim this cholesterol-reducing effect (soy protein foods; “Soybean fried chicken” made by Fuji Oil Co., Ltd.) have also become Ministry of Health and Welfare specified health foods.

【0004】このコレステロール低減能をはじめとする
生理機能は上述の様に、大豆蛋白質の中のある特定の画
分から発現されると考えられ、ペプチド成分としてのコ
レステロール低減能画分の特定については多くの研究が
なされている。菅野ら(Atherosclerosis, 72, 115, 198
8 及び J. Nutr., 120, 977, 1990)は、血中コレステロ
ール濃度低減効果には、大豆蛋白質の消化過程が深く関
わっているとし、大豆蛋白質のペプシンあるいは、微生
物プロテアーゼによる消化に際して得られる非消化性画
分は、きわめて顕著な降コレステロール作用を発揮する
ことをラットによるin vivo での研究で確認してきた。
As described above, the physiological functions including the cholesterol-reducing ability are considered to be expressed from a specific fraction of soybean protein, and many of the cholesterol-reducing fractions as peptide components are identified. Is being researched. Kanno et al. (Atherosclerosis, 72, 115, 198)
8 and J. Nutr., 120, 977, 1990) said that the process of soybean protein digestion was deeply involved in the effect of reducing blood cholesterol level, and that it was obtained by digestion of soybean protein with pepsin or microbial protease. It has been confirmed in an in vivo study in rats that the digestible fraction exerts a marked cholesterol-lowering effect.

【0005】in vitroでの研究ではあるが、岩見ら( 大
豆たん白質研究会会誌, 15, 74, 1994) は、血中コレス
テロールが、前駆体となっている胆汁酸との結合ペプチ
ドが大豆蛋白質の主要構成成分のひとつである11Sグ
ロブリンに存在し、さらにその構成成分である酸性サブ
ユニット中のアミノ酸14残基からなるペプチドである可
能性を示した。
Although it is an in vitro study, Iwami et al. (Journal of the Society of Soybean Protein Research, 15, 74, 1994) found that blood cholesterol is a soy protein that binds to bile acid as a precursor. It is present in 11S globulin, which is one of the major constituents of E.coli.

【0006】また、同じくin vitroでのコレステロール
低減能画分の研究ではあるが、Lovati M.R. ら(J. Agri
c. Food Chem.,46 , 2474, 1998)によると、悪玉コレス
テロールとして知られる低密度リポ蛋白質の人の肝細胞
での降下作用を検討したところ、11Sグロブリンと並
んで大豆蛋白質の主要構成成分である7Sグロブリンに
その効果があるとの結果を出している。以上のように、
大豆蛋白質の血中コレステロール低減能については大豆
蛋白質のどこに存在するのかは、未だはっきりした結論
が見出されていないのが現状である。
[0006] Similarly, in the in vitro study on the cholesterol-reducing fraction, Lovati MR et al. (J. Agri
c. Food Chem., 46, 2474, 1998), the effect of low-density lipoprotein known as bad cholesterol in human hepatocytes was examined, and it was found to be a major component of soybean protein along with 11S globulin. It has been shown that a certain 7S globulin has the effect. As mentioned above,
Regarding the blood cholesterol-reducing ability of soy protein, it is the present situation that no clear conclusion has yet been made as to where the soy protein exists.

【0007】[0007]

【発明が解決しようとする課題】本発明は、大豆蛋白質
中の血中コレステロール低減能画分を特定し、そのもの
を分画してコレステロール低減剤とし、医薬品として提
供するほか、コレステロール低減用の食料、食品、栄養
食品、機能性食品、特定保健用食品等飲食品タイプで使
用し、コレステロール低減のほか、コレステロール蓄積
の予防等に広く利用できることを課題とする。
DISCLOSURE OF THE INVENTION The present invention specifies a blood cholesterol-reducing fraction in soybean protein, fractionates the fraction as a cholesterol-reducing agent, and provides it as a pharmaceutical product. , Foods, nutritional foods, functional foods, foods for specified health use, etc., and to be widely used for cholesterol reduction as well as cholesterol accumulation prevention, etc.

【0008】[0008]

【課題を解決するための手段】本発明は、大豆蛋白質の
主要構成成分である11Sグロブリンを分画し、蛋白質
純度として70%以上好ましくは80%以上で分画され
た11Sグロブリンを有効成分とする血中コレステロー
ル低減用組成物とする。あるいは、育種技術により11
Sグロブリンを種子中の全蛋白質量の60%以上好まし
くは70%以上含む大豆より作製した分離大豆蛋白質を
有効成分とする血中コレステロール低減用組成物を得
る。
Means for Solving the Problems The present invention fractionates 11S globulin, which is a main component of soybean protein, and uses 11S globulin fractionated at a protein purity of 70% or more, preferably 80% or more as an active ingredient. A composition for reducing blood cholesterol. Alternatively, depending on the breeding technique, 11
A composition for reducing blood cholesterol containing an isolated soybean protein as an active ingredient, which is prepared from soybean containing S globulin in an amount of 60% or more, preferably 70% or more, of the total protein content in seeds.

【0009】[0009]

【発明の実施の形態】以下、本発明を詳細に説明する。
本発明での大豆蛋白質の主要構成成分である11Sグロ
ブリンの分画方法であるが、現在広く用いられいるタン
・シバサキの方法(Thahn,V.H., and Shibasaki ,K.,
J.Agric.Food Chem.,24, 117,1976)はもちろんである
が、その他いわゆるクリオプレシピテーション(Briggs,
D.R.and Mann,R.L., Cereal Chem, 27, 243,1950) に
よる冷却不溶区分(Cold-insoluble fraction/CIF と呼
ばれる)や、ウルフらによる(Wolf,W.J.and Sly,D.A., C
ereal Chem, 44, 653,1967) 0.1N塩化カルシウム添加
による分画法、また、大豆蛋白にフィチン酸分解活性を
有する酵素又は酵素剤を作用させる分画法等いずれの分
画法によっても良い。ただし、この際還元剤は用いずと
も十分使用に耐えうる純度の11Sグロブリンが分画で
き、さらにコレステロール低減剤として使用する場合も
還元剤を含まない方がより広い範囲の用途が期待でき
る。
BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be described in detail below.
The method for fractionating 11S globulin, which is a main component of soybean protein in the present invention, is the method of Tan Shibasaki, which is widely used at present (Thahn, VH, and Shibasaki, K.,
J. Agric. Food Chem., 24, 117, 1976), but also other so-called cryoprecipitation (Briggs,
DR-Mann, RL, Cereal Chem, 27, 243, 1950) and cold-insoluble fraction (called CIF), and Wolf et al. (Wolf, WJand Sly, DA, C
ereal Chem, 44, 653, 1967) Any fractionation method such as a fractionation method by adding 0.1N calcium chloride, or a fractionation method in which an enzyme having a phytate-decomposing activity or an enzyme agent is allowed to act on soybean protein may be used. However, in this case, 11S globulin having a purity sufficient for use can be fractionated without using a reducing agent, and when used as a cholesterol-reducing agent, the use of a reducing agent can be expected to have a wider range of applications.

【0010】あるいは、育種技術により11Sグロブリ
ンを種子中の全蛋白質量の60%、好ましくは70%以
上含む大豆から脱脂大豆を作製し、そこから還元剤を使
用しないこと以外は通常の分離大豆蛋白質の作製方法に
よって、純度70%、好ましくは80%以上の11Sグ
ロブリンが得られる。この場合も上述同様還元剤は用い
ずとも十分使用に耐えうる純度の11Sグロブリンが取
得でき、さらにコレステロール低減剤として使用する場
合も還元剤を含まない方がより広い範囲の用途が期待で
きる。
Ordinary isolated soybean protein except that defatted soybeans are produced from soybeans containing 60%, preferably 70% or more of the total protein content in seeds by a breeding technique and no reducing agent is used. According to the method for producing, 11S globulin having a purity of 70%, preferably 80% or more is obtained. In this case as well, 11S globulin with sufficient purity can be obtained without using a reducing agent as described above, and when used as a cholesterol-reducing agent, the use of a reducing agent can be expected to have a wider range of applications.

【0011】本発明において、11Sグロブリンとは、
一般に可溶性の球状蛋白質の総称であるグロブリンの
中、分子量の超遠心沈降係数が11Sに相当するものを
言う。グロブリンには分子量分布で2S、7S、11
S、15Sが存在し、その内、7Sと11Sが大豆の様
な豆科植物の貯蔵蛋白質には多量に含まれていることが
知られている。なお、大豆の11Sグロブリンはグリシ
ニンとも言われている。酸性サブユニットとは、上記の
11Sグロブリンを構成するポリペプチドの一つで、酸
性アミノ酸に富んでいる。塩基性サブユニットとは、1
1Sグロブリンを構成するポリペプチドの他の一つで、
塩基性アミノ酸に富んでいる。この塩基性サブユニット
と上記の酸性サブユニットとは、1個のジスルフィド
(S−S)結合により結合し、中間サブユニットを形成
している。11Sグロブリンはこの中間サブユニットが
6個会合したものである。
In the present invention, 11S globulin means
In general, globulin, which is a generic term for soluble globular proteins, refers to those having a molecular weight ultracentrifugal sedimentation coefficient of 11S. The globulin has a molecular weight distribution of 2S, 7S, 11
It is known that S and 15S exist, and among them, 7S and 11S are contained in large amounts in the storage proteins of legumes such as soybean. The 11S globulin of soybean is also called glycinin. The acidic subunit is one of the above 11S globulin-constituting polypeptides and is rich in acidic amino acids. Basic subunit is 1
Another of the polypeptides that make up 1S globulin,
Rich in basic amino acids. This basic subunit and the above acidic subunit are linked by one disulfide (SS) bond to form an intermediate subunit. 11S globulin is an association of six intermediate subunits.

【0012】本発明者らは鋭意検討の結果、次のことが
判った。 1)脱脂大豆より、大豆蛋白質成分の一般的な分画法で
あるタン・シバサキらによる方法によって分画する場
合、還元剤を使用せずとも70%以上の純度にまで分画
出来る。 2)上記11Sグロブリンと同時に精製した7Sグロブ
リンおよび11Sグロブリンの構成成分である酸性サブ
ユニットと塩基性サブユニットをそれぞれ分画し、カゼ
インを比較対照とした、ラットを用いた3週間の動物実
験により、11Sグロブリンのみが有意に血中コレステ
ロール低減能を有していた。
As a result of intensive studies, the present inventors have found the following. 1) Fractionation of defatted soybeans by a method according to Tan Shibasaki et al., Which is a general fractionation method of soybean protein components, can be performed to a purity of 70% or more without using a reducing agent. 2) A 3 week animal experiment using rats, in which the acid subunit and the basic subunit, which are the constituent components of 7S globulin and 11S globulin that were purified simultaneously with the above 11S globulin, were fractionated, and casein was used as a comparison control. , 11S globulin alone had the ability to significantly reduce blood cholesterol.

【0013】この中で、血中コレステロール低減能が1
1Sグロブリン中に存在し、それをその構成成分である
酸性サブユニットと塩基性サブユニットにまで分画して
経口投与すると、そこに存在する血中コレステロール低
減能の有効性が有意差を示さない程度にまで低減してし
まう結果は、意外な発見である。この原因として考えら
れるのは、大豆蛋白質の血中コレステロール低減能は1
1Sグロブリン中の酸性サブユニットと塩基性サブユニ
ットの何れかに存在するが、酸性サブユニットと塩基性
サブユニットにまで分画してから蛋白源として供与する
と、そこに存在する血中コレステロール低減能画分が消
化管で速やかに消化されてしまい、その効果を低下して
しまうと考えられる。
Among these, the blood cholesterol reduction ability is 1
When present in 1S globulin and fractionated into its constituent acidic subunits and basic subunits and administered orally, there is no significant difference in the effectiveness of blood cholesterol-reducing ability present therein. The result, which is reduced to a certain degree, is an unexpected discovery. It is thought that the cause of this is that soybean protein has a blood cholesterol-lowering ability of 1
It exists in either acidic subunits or basic subunits in 1S globulin, but if it is fractionated into acidic subunits and basic subunits and then donated as a protein source, it has the ability to reduce blood cholesterol existing there. It is considered that the fraction is promptly digested in the digestive tract and its effect is reduced.

【0014】また、血中コレステロール低減能が11S
グロブリンにのみ存在し、7Sグロブリンには存在しな
いことから、その成分の蛋白質画分、つまり大豆蛋白質
から11Sグロブリンへの精製度が向上している分、対
蛋白質当たりのコレステロール低減効果が、向上してい
ることは容易に考えられる。
The blood cholesterol-reducing ability is 11S.
Since it exists only in globulin and not in 7S globulin, the protein fraction of that component, that is, the degree of purification of soybean protein to 11S globulin, is improved, and the effect of reducing cholesterol per protein is improved. It is easy to think that.

【0015】従って、この11Sグロブリンをコレステ
ロール低減剤として経口投与する場合、その投与量は、
これまで分離大豆蛋白質で必要とされている、成人で1
日9gの半分ないしはそれ以下の3g程度で十分のコレ
ステロール低減効果が期待でき、さらにその投与形態
も、例えば、低減剤の形態(粉末状、糖衣錠、顆粒状
等)、賦形剤の種類と量、また食餌療法として食品に添
加しても、その効果が発揮できる。
Therefore, when this 11S globulin is orally administered as a cholesterol lowering agent, the dose is
1 for adults, so far required for isolated soy protein
About 3 g, which is half or less than 9 g per day, can be expected to have a sufficient cholesterol-reducing effect, and its administration form also includes, for example, the form of a reducing agent (powder, dragee, granule, etc.), the type and amount of excipient. Moreover, the effect can be exhibited even when added to food as dietary therapy.

【0016】[0016]

【実施例】以下に、本発明の有効性を実施例と共に示す
が、これらの例示によって本発明の技術思想が限定され
るものではない。
EXAMPLES The effectiveness of the present invention will be shown below together with examples, but the technical idea of the present invention is not limited by these examples.

【0017】製造例1(11Sグロブリンの調製) 脱脂大豆に1:10の重量割合で水を加え、随時pHを7.0
に調整しながら1時間撹拌し、この混合物を遠心分離
(4,000 r.p.m.,20℃で10分間) し、得られた上澄液
をpH6.4 に調整して、4℃にて一晩放置して、遠心分離
(4,000 r.p.m.,4℃にて10分間) して得られた沈殿物
を回収・加水後、pH7.0 に中和して殺菌後、噴霧乾燥し
たものを11Sグロブリンとした。このようにして得ら
れた11SグロブリンをSDS-ポリアクリルアミドゲル電
気泳動に供し、その後染色された蛋白質のバンドの染色
度の測定から、純度として85.4%あり、以下の検討に十
分耐えうる純度であることを確認した。
Production Example 1 (Preparation of 11S globulin) Water was added to defatted soybeans in a weight ratio of 1:10, and the pH was adjusted to 7.0 at any time.
Stir for 1 hour while adjusting to, centrifuge this mixture
(4,000 rpm, 20 ° C for 10 minutes), adjust the resulting supernatant to pH 6.4, leave at 4 ° C overnight, and centrifuge.
The precipitate obtained by (10 minutes at 4,000 rpm, 4 ° C.) was recovered and hydrated, neutralized to pH 7.0, sterilized, and spray dried to obtain 11S globulin. The thus obtained 11S globulin was subjected to SDS-polyacrylamide gel electrophoresis, and the degree of staining of the stained protein band was measured. As a result, the purity was 85.4%, which is sufficiently high for the following studies. It was confirmed.

【0018】製造例2(11Sグロブリンを多く含む大
豆からの分離大豆蛋白質の調製) 育種技術により、11Sグロブリンを種子中の全蛋白質
量の71.2%含む大豆の脱脂大豆に1:10の重量割合で
水を加え、随時pHを7.0 に調整しながら1時間撹拌し、
この混合物を遠心分離(4,000 r.p.m., 20℃で10分間)
し、得られた上澄液をpH5.5 に調整して、遠心分離(4,0
00 r.p.m.,4℃にて10分間) して得られた沈殿物を回
収・加水後、pH7.0 に中和して殺菌し、噴霧乾燥したも
のを分離大豆蛋白とした。このようにして得られた分離
大豆蛋白をSDS-ポリアクリルアミドゲル電気泳動に供
し、その後染色された蛋白質のバンドの染色度の測定か
ら、純度として78.6%あり、以下の検討に十分耐えうる
純度であることを確認した。
Production Example 2 (Preparation of isolated soybean protein from soybeans containing a large amount of 11S globulin) By a breeding technique, defatted soybeans containing 11S globulin in an amount of 71.2% of the total protein amount in seeds were used in a weight ratio of 1:10. Add water and stir for 1 hour while adjusting the pH to 7.0 at any time,
Centrifuge this mixture (4,000 rpm, 20 ° C for 10 minutes)
The pH of the resulting supernatant was adjusted to pH 5.5 and centrifuged (4,0
The precipitate thus obtained was collected and hydrated, neutralized to pH 7.0, sterilized, and spray-dried to obtain isolated soybean protein. The isolated soybean protein thus obtained was subjected to SDS-polyacrylamide gel electrophoresis, and then the degree of staining of the stained protein band was measured to find that the purity was 78.6%. I confirmed that there is.

【0019】製造例3(11Sグロブリンより各サブユ
ニットの分離・分画) 上記により得られた14.2% 濃度の11Sグロブリン溶液
を、吹き込み水蒸気圧6 kgf/cm2の水蒸気殺菌装置に供
し、2秒間の水蒸気吹き込み後、140℃にて1分間の
高温を保持した。溶液が50℃程度にまで冷却されてか
ら、遠心分離(8,000 r.p.m.,20℃前後にて10分間)
して上澄と沈殿に分画した。上澄はそのまま凍結乾燥
し、沈殿には沈殿の重量とほぼ等量の水を加えて懸濁し
た後、凍結乾燥した。この様にして得られた各サブユニ
ットをSDS-ポリアクリルアミドゲル電気泳動に供してそ
のパターンを調べた。その結果、上澄画分の酸性サブユ
ニット純度は93.6%あり、塩基性サブユニットの混入は
認められなかった。また、沈殿画分の塩基性サブユニッ
ト純度は83.9%で、酸性サブユニットは検出されなかっ
た。
Production Example 3 (Separation and Fractionation of Subunits from 11S Globulin) The 11.2% concentration 11S globulin solution obtained above was supplied to a steam sterilizer having a steam pressure of 6 kgf / cm 2 for 2 seconds. After blowing in the steam, the temperature was kept at 140 ° C. for 1 minute. Centrifuge (10 min at 8,000 rpm, 20 ° C) after the solution is cooled to about 50 ° C.
Then, it was fractionated into a supernatant and a precipitate. The supernatant was lyophilized as it was, and the precipitate was suspended by adding water in an amount substantially equal to the weight of the precipitate, and then lyophilized. Each of the subunits thus obtained was subjected to SDS-polyacrylamide gel electrophoresis to examine its pattern. As a result, the purity of the acidic subunit in the supernatant fraction was 93.6%, and no contamination with the basic subunit was observed. The purity of the basic subunit in the precipitated fraction was 83.9%, and no acidic subunit was detected.

【0020】製造例4(7Sグロブリンの調製) 上記製造例1での4 ℃にて一晩放置して、遠心分離(4,0
00 r.p.m.,4℃にて10分間) して得られた上澄液側
を、pH4.5 に調整して、遠心分離(4,000 r.p.m.,4℃に
て10分間) して得られた沈殿物を回収・加水後、pH7.
0 に中和して殺菌し、噴霧乾燥したものを7Sグロブリ
ンとした。このようにして得られた7SグロブリンはSD
S-ポリアクリルアミドゲル電気泳動の結果、純度として
72.4%あり、以下の検討に十分耐えうる純度であること
を確認した。
Production Example 4 (Preparation of 7S globulin) The mixture was left overnight at 4 ° C. in the above Production Example 1 and centrifuged (4.00).
The supernatant obtained by (00 rpm, 4 ° C for 10 minutes) was adjusted to pH 4.5, and the precipitate obtained by centrifugation (4,000 rpm, 4 ° C for 10 minutes) was used. PH 7.
The product was neutralized to 0, sterilized, and spray-dried to give 7S globulin. The 7S globulin thus obtained is SD
As a result of S-polyacrylamide gel electrophoresis,
It was 72.4%, and it was confirmed that the purity was sufficient to withstand the following studies.

【0021】実施例1(ラットによる血中コレステロー
ル低減効果確認試験) ラットによる血中コレステロール低減効果確認試験であ
るが、その試験資料の配合は、上記製造例2を除く、製
造例1から4にてそれぞれ得られた各大豆蛋白質成分と
比較対照としてカゼイン(ビタミンフリーカゼイン、オ
リエンタル酵母(株)製)をそれぞれ食餌蛋白質として
20%含み、コレステロール 0.5% とコール酸ナトリウ
ム 0.125% を添加し、さらにシュクロースとコーンスタ
ーチの混合比率を1:2としたものを用いた。具体的配
合を下記表1に記す。
Example 1 (Confirmation Test for Blood Cholesterol Reduction Effect in Rats) This is a blood cholesterol reduction effect confirmation test in rats. The test materials are compounded in Production Examples 1 to 4 except for the above Production Example 2. Each of the soybean protein components obtained as a result and casein (vitamin-free casein, manufactured by Oriental Yeast Co., Ltd.) as a comparison protein contained 20% as dietary protein, and 0.5% cholesterol and 0.125% sodium cholate were added. A mixture having a mixing ratio of claus and corn starch of 1: 2 was used. The specific formulation is shown in Table 1 below.

【0022】[0022]

【表1】 [Table 1]

【0023】実験動物は5週齢のウィスター系雄ラット
(体重90g から110g程度のラット)を日本SLCより購
入し、市販固形飼料(オリエンタル「CRF−1」)で
1週間予備飼育した後、各試験資料群の体重が揃うよう
に1群6匹で計5群に分け、試験飼料で3週間飼育し
た。飼育はラットを個別ケージに1匹ずつ入れ、温度2
3±1℃、湿度55±5%で12時間明暗サイクル(7:
00から19:00 まで照明)の下で行った。飼育期間中は水
および飼料を自由摂取させた。
As test animals, 5-week-old Wistar male rats (rats weighing 90 g to 110 g) were purchased from Japan SLC and preliminarily bred for 1 week with a commercial solid feed (Oriental "CRF-1"). The test material group was divided into 5 groups with 6 animals so that the body weight was uniform, and the test material group was fed with the test feed for 3 weeks. As for the breeding, one rat is placed in each cage and the temperature is set to 2
12 hours light-dark cycle (3: 1 ℃, humidity 55 ± 5%)
I went under the lights from 00 to 19:00). During the rearing period, water and feed were freely available.

【0024】試験期間は21日間とし、その期間の体重の
増加を測定し、下記表2の結果を得た。なお、各試験間
の体重の増加量に有意差は認められなかった。
The test period was 21 days, and the increase in body weight during that period was measured, and the results shown in Table 2 below were obtained. No significant difference was found in the amount of increase in body weight between the tests.

【0025】[0025]

【表2】 [Table 2]

【0026】21日間の試験食終了後、22日目の朝
(AM8:00)より6時間絶食し、ネンブタール麻酔下で開
腹後、ヘパリン処理した注射器で腹部大動脈より採血し
た。血液から遠心分離(3,000 r.p.m.,5℃にて10分
間) にて血漿を分離し、総コレステロールの濃度を測定
した。なお、測定値については各2群間でのt検定にて
有意差検定を行った。その結果を表3に示す。
After the 21-day test meal was completed, the animals were fasted for 6 hours from the morning of 22nd day (AM8: 00), and after laparotomy under Nembutal anesthesia, blood was collected from the abdominal aorta with a heparinized syringe. Plasma was separated from blood by centrifugation (3,000 rpm, 5 ° C for 10 minutes), and the concentration of total cholesterol was measured. Regarding the measured values, a significant difference test was performed by t-test between each two groups. The results are shown in Table 3.

【0027】[0027]

【表3】 [Table 3]

【0028】[0028]

【発明の効果】 本発明により、血中コレステロール濃
度を効率的に低減せしめることができ、しかも安全性が
きわめて高いので、血中コレステロールの濃度低減のた
めの予防ないし、治療剤として有用であるだけでなく、
そのための飲食品としても提供することが出来る。
EFFECTS OF THE INVENTION Since the present invention can efficiently reduce blood cholesterol concentration and has extremely high safety, it is only useful as a prophylactic or therapeutic agent for reducing blood cholesterol concentration. Not
It can also be provided as food and drink for that purpose.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 青山 敏明 大阪府泉佐野市住吉町1番地 不二製油株 式会社阪南事業所内 (72)発明者 橋本 征雄 大阪府泉佐野市住吉町1番地 不二製油株 式会社阪南事業所内 (72)発明者 鬼頭 誠 京都府京都市左京区下鴨下川原町46−72 Fターム(参考) 4B018 MD20 MD58 ME04 MF01 4C084 AA07 CA15 DA38 NA05 NA14 ZA362 ZC332 4C088 AB59 AC04 BA16 CA21 NA05 NA14 ZA36 ZC33    ─────────────────────────────────────────────────── ─── Continued front page    (72) Inventor Toshiaki Aoyama             1 Sumiyoshi-cho, Izumisano-shi, Osaka Fuji Oil Co., Ltd.             Ceremony company Hannan office (72) Inventor Masao Hashimoto             1 Sumiyoshi-cho, Izumisano-shi, Osaka Fuji Oil Co., Ltd.             Ceremony company Hannan office (72) Inventor Makoto Kitou             46-72 Shimogamo Shimogawaracho, Sakyo Ward, Kyoto City, Kyoto Prefecture F term (reference) 4B018 MD20 MD58 ME04 MF01                 4C084 AA07 CA15 DA38 NA05 NA14                       ZA362 ZC332                 4C088 AB59 AC04 BA16 CA21 NA05                       NA14 ZA36 ZC33

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 大豆蛋白質から蛋白質純度として70%
以上で分画された11Sグロブリンを有効成分とする血
中コレステロール低減用組成物。
1. A protein purity of 70% from soybean protein.
A composition for reducing blood cholesterol, which comprises 11S globulin fractionated as described above as an active ingredient.
【請求項2】 11Sグロブリンを大豆種子中の全蛋白
質量の60%以上含む大豆より作製した分離大豆蛋白質
を有効成分とする血中コレステロール低減用組成物。
2. A composition for reducing blood cholesterol, which comprises isolated soybean protein prepared from soybean containing 11S globulin in an amount of 60% or more of the total protein content of soybean seeds as an active ingredient.
【請求項3】 その製造工程において還元剤を添加しな
いで作製された請求項1ないし2の血中コレステロール
低減用組成物。
3. The composition for reducing blood cholesterol according to claim 1, which is produced without adding a reducing agent in the production process.
JP09331299A 1999-03-31 1999-03-31 Composition for reducing cholesterol in blood Pending JP2003088334A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP09331299A JP2003088334A (en) 1999-03-31 1999-03-31 Composition for reducing cholesterol in blood
AU34549/00A AU3454900A (en) 1999-03-31 2000-03-30 Compositions for reducing blood cholesterol
PCT/JP2000/001994 WO2000057898A1 (en) 1999-03-31 2000-03-30 Compositions for reducing blood cholesterol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP09331299A JP2003088334A (en) 1999-03-31 1999-03-31 Composition for reducing cholesterol in blood

Publications (1)

Publication Number Publication Date
JP2003088334A true JP2003088334A (en) 2003-03-25

Family

ID=14078811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09331299A Pending JP2003088334A (en) 1999-03-31 1999-03-31 Composition for reducing cholesterol in blood

Country Status (3)

Country Link
JP (1) JP2003088334A (en)
AU (1) AU3454900A (en)
WO (1) WO2000057898A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086437A1 (en) * 2002-04-12 2003-10-23 Ajinomoto Co., Inc. Composition for preventing arteriosclerosis
WO2006101181A1 (en) * 2005-03-23 2006-09-28 Fuji Oil Company, Limited Composition for prevention or improvement of liver dysfunction, and method for preventing or improving liver dysfunction
US7357951B2 (en) 2002-04-12 2008-04-15 Ajinomoto Co., Inc. Composition for preventing atherosclerosis
US8586529B2 (en) 2006-07-31 2013-11-19 J-Oil Mills, Inc. Composition for preventing and improving metabolic syndrome
US9101158B2 (en) 2011-06-07 2015-08-11 Fuji Oil Company Limited Application of soybean emulsion composition to soybean-derived raw material-containing food or beverage

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171640B1 (en) * 1997-04-04 2001-01-09 Monsanto Company High beta-conglycinin products and their use

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086437A1 (en) * 2002-04-12 2003-10-23 Ajinomoto Co., Inc. Composition for preventing arteriosclerosis
US7357951B2 (en) 2002-04-12 2008-04-15 Ajinomoto Co., Inc. Composition for preventing atherosclerosis
US7485328B2 (en) 2002-04-12 2009-02-03 Ajinomoto Co., Inc. Composition for preventing atherosclerosis
WO2006101181A1 (en) * 2005-03-23 2006-09-28 Fuji Oil Company, Limited Composition for prevention or improvement of liver dysfunction, and method for preventing or improving liver dysfunction
US8586529B2 (en) 2006-07-31 2013-11-19 J-Oil Mills, Inc. Composition for preventing and improving metabolic syndrome
US9101158B2 (en) 2011-06-07 2015-08-11 Fuji Oil Company Limited Application of soybean emulsion composition to soybean-derived raw material-containing food or beverage

Also Published As

Publication number Publication date
AU3454900A (en) 2000-10-16
WO2000057898A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
Yalcin Emerging therapeutic potential of whey proteins and peptides
CN101305017B (en) Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same
CA1338682C (en) Biologically active undenatured whey protein concentrate as food supplement
US5290571A (en) Biologically active whey protein concentrate
CA2435392C (en) Desiccated avian sternal cartilage powder
US20060280804A1 (en) Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis
Kassem Future challenges of whey proteins
JP2002535288A (en) Lipoprotein complexes and compositions containing them
JP2805194B2 (en) Peptide for increasing blood triglyceride concentration and blood triglyceride concentration increase inhibitor containing the peptide as an active ingredient
JP4461680B2 (en) Composition for reducing blood neutral fat
JP3068656B2 (en) Novel peptide and angiotensin converting enzyme inhibitory peptide and oral feeding composition containing them
EP2164515A1 (en) Method for the treatment of atopic eczema
JP2003088334A (en) Composition for reducing cholesterol in blood
JP2003210138A (en) Functional food, method for producing the same, and medicine
JPH06165655A (en) Composition for reducing cholesterol
JP2002114694A (en) Blood cholesterol lowering composition
JPH07215851A (en) Antiallergic agent and its production
KR20030015537A (en) Process for preparing a peptide lowering blood lipid level
EP1541160A1 (en) Body fat percentage-lowering agent or body fat percentage increase inhibitor
MXPA01001537A (en) Protein component for dietetic food.
JP2007110901A (en) Composition for diminishing neutral in blood
Sgarbieri Food Proteins and Peptides Presenting Specific Protection to Human Health (A Review)
TWI686204B (en) Use of milk-derived basic protein fraction and/or a degradation product of a milk-derived basic protein fraction, and a whey protein hydrosylate
Recio et al. Engineered food/protein structure and bioactive proteins and peptides from whey
AU638441B2 (en) Biologically active whey protein composition, a method for producing it and use of the composition